Free Access
Med Sci (Paris)
Volume 26, Number 10, Octobre 2010
Page(s) 803 - 807
Section Nouvelles
Published online 15 October 2010
  1. Morris DL, Rui L. Recent advances in understanding leptin signaling and leptin resistance. Am J Physiol Endocrinol Metab 2009 ; 297 : E1247-59. [Google Scholar]
  2. Farooqi IS, Jebb SA, Langmack G, et al. Effects of recombinant leptin therapy in a child with congenital leptin deficiency. N Engl J Med 1999 ; 341 : 879-84. [Google Scholar]
  3. Farooqi IS, Matarese G, Lord GM, et al. Beneficial effects of leptin on obesity, T cell hyporesponsiveness, and neuroendocrine/metabolic dysfunction of human congenital leptin deficiency. J Clin Invest 2002 ; 110 : 1093-103. [Google Scholar]
  4. Capeau J, Magré J, Caron-Debarle M, et al. Human lipodystrophies: genetic and acquired diseases of adipose tissue. Endocr Dev 2010 ; 19 : 1-20. [Google Scholar]
  5. Oral EA, Simha V, Ruiz E, et al. Leptin-replacement therapy for lipodystrophy. N Engl J Med, 2002 ; 346 : 570-8. [Google Scholar]
  6. Petersen KF, Oral EA, Dufour S, et al. Leptin reverses insulin resistance and hepatic steatosis in patients with severe lipodystrophy. J Clin Invest 2002 ; 109 : 1345-50. [Google Scholar]
  7. Chong AY, Lupsa BC, Cochran EK, Gorden P. Efficacy of leptin therapy in the different forms of human lipodystrophy. Diabetologia 2010 : 53 : 27-35. [Google Scholar]
  8. Beltrand J, Beregszaszi M, Chevenne D, et al. Metabolic correction induced by leptin replacement treatment in young children with Berardinelli-Seip congenital lipoatrophy. Pediatrics 2007 ; 120 : e291-6. [Google Scholar]
  9. Unger RH, Clark GO, Scherer PE, Orci L. Lipid homeostasis, lipotoxicity and the metabolic syndrome. Biochim Biophys Acta 2010 ; 1801 : 209-14. [Google Scholar]
  10. Beltrand J, Lahlou N, Le Charpentier T, et al. Resistance to leptin replacement therapy in Berardinelli-Seip congenital lipodystrophy (BSCL): an immunological origin. Eur J Endocrinol 2010 ; 162 : 1083-91. [Google Scholar]
  11. Kusakabe T, Tanioka H, Ebihara K, et al. Beneficial effects of leptin on glycaemic and lipid control in a mouse model of type 2 diabetes with increased adiposity induced by streptozotocin and a high-fat diet. Diabetologia 2009 ; 52 : 675-83. [Google Scholar]
  12. Seufert J. Leptin effects on pancreatic beta-cell gene expression and function. Diabetes 2004 ; 53 (suppl 1) : S152-8. [Google Scholar]
  13. Park S, Ahn IS, Kim da S. Central infusion of leptin improves insulin resistance and suppresses beta-cell function, but not beta-cell mass, primarily through the sympathetic nervous system in a type 2 diabetic rat model. Life Sci 2010 ; 86 : 854-62. [Google Scholar]
  14. Wang MY, Chen L, Clark GO, et al. Leptin therapy in insulin-deficient type I diabetes. Proc Natl Acad Sci USA 2010 ; 107 : 4813-9. [Google Scholar]
  15. Chinookoswong N, Wang JL, Shi ZQ. Leptin restores euglycemia and normalizes glucose turnover in insulin-deficient diabetes in the rat. Diabetes 1999 ; 48 : 1487-92. [Google Scholar]
  16. Miyanaga F, Ogawa Y, Ebihara K, et al. Leptin as an adjunct of insulin therapy in insulin-deficient diabetes. Diabetologia 2003 ; 46 : 1329-37. [Google Scholar]
  17. Yu X, Park BH, Wang MY, et al. Making insulin-deficient type 1 diabetic rodents thrive without insulin. Proc Natl Acad Sci USA 2008 ; 105 : 14070-5. [Google Scholar]
  18. Koh KK, Park SM, Quon MJ. Leptin and cardiovascular disease: response to therapeutic interventions. Circulation 2008 ; 117 : 3238-49. [Google Scholar]

Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.

Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.

Initial download of the metrics may take a while.